山外山(688410.SH):全資子公司取得醫療器械註冊證
格隆匯7月11日丨山外山(688410.SH)公佈,公司全資子公司重慶天外天生物技術有限公司於近日收到由國家藥品監督管理局頒發的《中華人民共和國醫療器械註冊證》,產品名稱為血液透析濃縮液,本品適用於急、慢性腎功能衰竭患者的血液透析治療。
公司本次取得上述產品註冊證,標誌着公司在持續拓展產品組合方面取得了顯著進展,同時也加快了血液淨化耗材在研產品的商業化步伐;不僅滿足了市場上多樣化的需求,還為公司的相關產品銷售注入了動力,從而有助於增強公司的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.